USPTO Examiner SALMON KATHERINE D - Art Unit 1682

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18829672Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VEGFSeptember 2024October 2025Allow1431YesYes
18720668MULTIPLE KASP MARKER PRIMER SET FOR WHEAT PLANT HEIGHT MAJOR GENES AND USE THEREOFJune 2024February 2026Allow2010NoNo
18739680KIT, DEVICE, AND METHOD FOR DETECTING LUNG CANCERJune 2024June 2025Allow1311NoNo
18646971Kit for Assaying AFP mRNA for Liver Cancer DiagnosisApril 2024January 2025Abandon810NoNo
18632749CELL-FREE DETECTION OF METHYLATED BREAST TUMORApril 2024January 2026Allow2111YesNo
18632776CELL-FREE DETECTION OF METHYLATED PROSTATE TUMOURApril 2024January 2026Allow2111YesNo
18624594DETECTION METHODSApril 2024August 2025Allow1711YesNo
18614496METHOD OF MEASURING CHIMERISMMarch 2024May 2025Abandon1401NoNo
18444053METHODS FOR EARLY PREDICTION, TREATMENT RESPONSE, RECURRENCE AND PROGNOSIS MONITORING OF PANCREATIC CANCERFebruary 2024November 2024Allow911YesNo
18422247ASSAYS FOR FUNGAL INFECTIONJanuary 2024July 2025Allow1711YesNo
18421579ASSAYS FOR FUNGAL INFECTIONJanuary 2024April 2025Allow1410NoNo
18408056KIT, DEVICE AND METHOD FOR DETECTING PROSTATE CANCERJanuary 2024January 2025Allow1211NoNo
18504402COMBINATIONS, DETECTION METHODS AND KITS OF DNA METHYLATION BIOMARKERNovember 2023July 2025Allow2011YesNo
18500680PREPARATION OF TEMPLATES FOR METHYLATION ANALYSISNovember 2023April 2025Allow1711YesNo
18350566HIGHLY STABLE AND SPECIFIC MOLECULAR BEACONS ENCAPSULATED IN CATIONIC LIPOPLEX NANOPARTICLES AND APPLICATION THEREOFJuly 2023December 2024Abandon1701NoNo
18344010MOLECULAR SUBTYPING OF SMALL CELL LUNG CANCER TO PREDICT THERAPEUTIC RESPONSESJune 2023January 2026Allow3131NoNo
18302737BREAST CANCER SPLICE VARIANTSApril 2023April 2025Abandon2421NoNo
18165089DEVICES AND METHODS FOR MOLECULE DETECTION BASED ON THERMAL STABILITIES OF MAGNETIC NANOPARTICLESFebruary 2023August 2024Allow1811NoNo
18160468Detection of Chemicals and Molecules Using Cell-free Biosensor Lateral Flow AssaysJanuary 2023February 2026Abandon3701NoNo
18016021DETERMINING CANCER RESPONSIVENESS TO TREATMENTJanuary 2023February 2026Abandon3701NoNo
18003243KIT FOR HIGH-THROUGHPUT SEQUENCING (HTS) OF HUMAN MITOCHONDRIAL GENOME BY DIRECT AMPLIFICATION WITH FUSION PRIMERDecember 2022January 2026Abandon3701NoNo
18010914SMARCA4 INHIBITION FOR THE TREATMENT OF CANCERDecember 2022January 2026Abandon3701NoNo
18083221METHODS FOR PROSTATE CANCER DETECTIONDecember 2022January 2025Allow2621YesNo
18067661MULTIMODAL ANALYSIS OF CIRCULATING TUMOR NUCLEIC ACID MOLECULESDecember 2022June 2025Abandon3021YesNo
17991739METHODS AND SYSTEMS FOR DETECTING TISSUE CONDITIONSNovember 2022December 2024Abandon2411NoNo
17998844KITS AND METHODS FOR DETERMINING COPY NUMBER OF MOUSE TCR GENENovember 2022November 2025Allow3610NoNo
18050855METHODS AND SYSTEMS FOR IMPROVING PATIENT MONITORING AFTER SURGERYOctober 2022January 2024Abandon1531YesNo
17960026CUSTOMIZED ASSAYS FOR PERSONALIZED CANCER MONITORINGOctober 2022January 2025Allow2731YesNo
17914759METHODS, COMPOSITIONS AND KITS FOR HLA TYPINGSeptember 2022January 2026Abandon4001YesNo
17913549PREDICTION OF RADIOTHERAPY RESPONSE FOR PROSTATE CANCER SUBJECT BASED ON DNA REPAIR GENESSeptember 2022November 2025Abandon3771YesNo
17913724PREDICTION OF RADIOTHERAPY RESPONSE FOR PROSTATE CANCER SUBJECT BASED ON CHEMOKINE GENESSeptember 2022January 2026Abandon4001NoNo
17887727COMPOSITIONS AND METHODS FOR ONCOLOGY PRECISION ASSAYSAugust 2022July 2025Allow3551NoNo
17883512SYSTEMS AND METHODS FOR QUALITY CONTROL IN DIGITAL PROCESSESAugust 2022December 2025Abandon4010NoNo
17817452BIOMARKERS FOR HEAD AND NECK CANCER AND METHODS OF THEIR USEAugust 2022January 2025Allow3021YesNo
17812415OPTIMIZATION OF MULTIGENE ANALYSIS OF TUMOR SAMPLESJuly 2022August 2024Allow2511NoNo
17810816Methods Of Treating Skin Cancer With Histidine Ammonia-Lyase (HAL) AgonistsJuly 2022August 2024Allow2611YesNo
17596594METHODS OF DETECTING AND PREDICTING BREAST CANCERJune 2022January 2026Abandon4901NoNo
17837731UNBIASED DNA METHYLATION MARKERS DEFINE AN EXTENSIVE FIELD DEFECT IN HISTOLOGICALLY NORMAL PROSTATE TISSUES ASSOCIATED WITH PROSTATE CANCER: NEW BIOMARKERS FOR MEN WITH PROSTATE CANCERJune 2022November 2024Allow2941YesNo
17751201Methods and Processes for Non-Invasive Assessment of Genetic VariationsMay 2022July 2024Allow2611YesNo
17743698Methods of Detecting Trichomonas VaginalisMay 2022September 2024Allow2921YesNo
17774592IRON-SCORE AND IN VITRO METHOD FOR IDENTIFYING HIGH RISK DLBCL SUBJECTS AND THERAPEUTIC USES AND METHODSMay 2022November 2025Abandon4201NoNo
17713143Method of Determining and Treating Breast CancerApril 2022February 2025Allow3421YesNo
17642753CA-IX APTAMERS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOFMarch 2022July 2025Allow4101YesNo
17694306BCR-ABL VARIANTSMarch 2022July 2024Allow2821YesNo
17561077PROCESSES, MACHINES, AND COMPOSITIONS RELATED TO ANALYZING NEOPLASMS SUCH AS CANCERDecember 2021November 2023Abandon2321NoNo
17554966METHODS AND COMPOSITIONS FOR PROGNOSIS AND TREATMENT OF CANCERSDecember 2021June 2025Allow4221NoNo
17554195METHOD FOR DETERMINING COPY NUMBER VARIATIONSDecember 2021October 2025Allow4631NoNo
17616149Methods and Kits for Detection of N-4-acetyldeoxycytidine in DNADecember 2021May 2025Abandon4101NoNo
17527576Polymerase Chain Reaction Primers and Probes for Mycobacterium TuberculosisNovember 2021July 2024Allow3231YesNo
17523325METHODS FOR ASSESSING THE PURITY OF A MESENCHYMAL STEM CELLS PREPARATIONNovember 2021January 2025Abandon3821NoNo
17504058WHOLE-GENOME HAPLOTYPE RECONSTRUCTIONOctober 2021August 2024Allow3411NoNo
17604301METHOD AND KIT FOR THE IDENTIFICATION OF VACCINIUM MYRTILLUSOctober 2021November 2025Allow4921NoNo
17602161SAMPLE ANALYSIS DEVICEOctober 2021April 2025Allow4220YesNo
17496641METHOD FOR DETERMINING RCC SUBTYPESOctober 2021January 2026Abandon5221NoNo
17494465METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERSOctober 2021June 2025Abandon4401NoNo
17489677METHODS AND SYSTEMS TO IMPROVE THE SIGNAL TO NOISE RATIO OF DNA METHYLATION PARTITIONING ASSAYSSeptember 2021September 2025Allow4741YesNo
17481374SSB METHODSeptember 2021April 2025Allow4331YesNo
17459477SELECTION AND TREATMENT OF CANCER WITH COMBINATION THERAPIESAugust 2021December 2024Abandon4031NoNo
17395244METHOD FOR IDENTIFYING HIGH-RISK AML PATIENTSAugust 2021June 2025Abandon4711NoNo
17310116SCREENING METHODJuly 2021June 2025Abandon4701NoNo
17422967COMPOSITIONS AND METHODS FOR TEMPLATE-FREE GEOMETRIC ENZYMATIC NUCLEIC ACID SYNTHESISJuly 2021November 2025Allow5211YesNo
17366248METHODS AND SYSTEMS FOR ENRICHMENT OF BARCODESJuly 2021December 2025Abandon5321YesNo
17357862HIGHLY STABLE AND SPECIFIC MOLECULAR BEACONS ENCAPSULATED IN CATIONIC LIPOPLEX NANOPARTICLES AND APPLICATION THEREOFJune 2021August 2024Allow3811YesNo
17415747METHOD FOR SIMULTANEOUSLY DETECTING EXOSOME MEMBRANE PROTEIN AND MRNAJune 2021February 2025Abandon4410NoNo
17349734METHODS FOR ANALYSIS OF CELL-FREE RNAJune 2021March 2025Abandon4531NoNo
17413173MIRNAS AS BIOMARKERS FOR PARKINSON'S SYNDROMEJune 2021April 2025Abandon4611NoNo
17311442COMPOSITIONS AND METHODS FOR DETECTION OF CANDIDA AURISJune 2021February 2025Allow4511NoNo
17294364METHOD FOR DETECTION OF RNAMay 2021February 2026Abandon5730YesNo
17307236METHOD FOR PREDICTING THE CLINICAL RESPONSE OF ONCOLYTIC PARVOVIRUS H1 (H-1PV) TREATMENT IN A PATIENT SUSPECTED OF SUFFERING FROM CANCER BY MEASURING THE EXPRESSION LEVELS OF LAMININS AND/OR GALECTINS AS BIOMARKERS IN A PATIENT'S SAMPLEMay 2021August 2025Allow5221YesNo
17289803USES OF METHYLATED LOCI IN SONIC HEDGEHOG MEDULLOBLASTOMAApril 2021August 2025Abandon5221YesNo
17239207TUMOR GRADING AND CANCER PROGNOSISApril 2021August 2025Allow5211YesNo
17287132USE OF LONG NON-CODING RNA FOR THE DIAGNOSIS OF PROSTATE CANCERApril 2021August 2025Abandon5221NoNo
17286483PROBE HAVING OCTAMINE OR OCTAMINE DERIVATIVE BOUND THERETO, AND USES OF SAMEApril 2021November 2024Abandon4310NoNo
17231725METHODS AND SYSTEMS FOR TARGET SCREENINGApril 2021February 2025Abandon4611YesNo
17285456METHODS AND KITS FOR DETECTING CELLS USING OLIGONUCLEOTIDE CONJUGATED ANTIBODIESApril 2021July 2025Abandon5111NoNo
17282305METHODS AND COMPOSITIONS FOR HIGH SENSITIVITY DETECTION OF DRUG RESISTANCE MARKERSApril 2021June 2025Abandon5102NoNo
17206895BIOMARKERS OF RESPONSE TO HIF-2-ALPHA INHIBITION IN CANCER AND METHODS FOR THE USE THEREOFMarch 2021August 2024Allow4121NoNo
17263708METHOD OF MONITORING EFFECTIVENESS OF IMMUNOTHERAPY OF CANCER PATIENTSJanuary 2021June 2025Abandon5241NoNo
17257991TRANSPOSOME ENABLED DNA/RNA-SEQUENCING (TED RNA-SEQ)January 2021November 2024Abandon4620NoNo
15734363METHODS FOR DEVELOPING URINE BIOMARKERS AND FOR DETECTING BLADDER CANCERDecember 2020April 2025Allow5211YesNo
17054204MOLECULAR GENE SIGNATURES AND METHODS OF USING SAMENovember 2020September 2024Allow4611NoNo
17053688METHODS FOR EARLY PREDICTION, TREATMENT RESPONSE, RECURRENCE AND PROGNOSIS MONITORING OF BREAST CANCERNovember 2020November 2024Allow4831YesNo
16970749CELL FREE DNA DECONVOLUSION AND USE THEREOFAugust 2020September 2025Abandon6043NoNo
16963065PHENOTYPIC AGE AND DNA METHYLATION BASED BIOMARKERS FOR LIFE EXPECTANCY AND MORBIDITYJuly 2020September 2025Abandon6031YesYes
16929512RADIATION BIODOSIMETRY SYSTEMSJuly 2020January 2025Abandon5441NoNo
16954370COMPOSTIONS AND METHODS FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILESJune 2020October 2024Allow5251YesNo
16859655IDENTIFICATION OF POLYMORPHIC SEQUENCES IN MIXTURES OF GENOMIC DNAApril 2020June 2025Allow6021NoNo
16650849RISK DETERMINATION FOR NEOPLASIA AND CANCERMarch 2020February 2025Allow5961NoNo
16641634METHODS OF SELECTING A TREATMENT FOR CANCER PATIENTSFebruary 2020October 2025Abandon6021YesYes
16637372METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCERFebruary 2020August 2024Allow5441YesNo
16428735PRODUCTS AND PROCESSES FOR NUCLEIC ACID DETECTION AND QUANTIFICATIONMay 2019August 2024Allow6041NoNo
16342758HIGH RESOLUTION SPATIAL GENOMIC ANALYSIS OF TISSUES AND CELL AGGREGATESApril 2019August 2024Allow6041YesNo
16309271COMPOSITIONS AND METHODS FOR DETECTION OF NUCLEIC ACID MUTATIONSDecember 2018June 2025Abandon6071YesNo
16099451METHODS FOR CLASSIFYING PATIENTS WITH A SOLID CANCERNovember 2018August 2024Abandon6081YesNo
16098455CELL-FREE DETECTION OF METHYLATED TUMOUR DNANovember 2018April 2025Allow6072YesNo
16016460METHODS AND COMPOSITIONS FOR THE ANALYSIS OF CANCER BIOMARKERSJune 2018January 2025Allow6071YesNo
15730382N-ACETYL-alpha-D-GLUCOSAMINIDASE DEFICIENCY COMPOSITIONS AND METHODSOctober 2017January 2020Allow2721NoNo
15520990BIOMARKERS FOR PREDICTING WEIGHT LOSS AND WEIGHT MAINTENANCEApril 2017February 2020Allow3431YesNo
15502418MICRORNAS CHARACTERIZING ACNE AND THE USES THEREOFFebruary 2017January 2020Allow3531YesNo
15201302METHOD FOR HIGH SENSITIVITY DETECTION OF MYD88 MUTATIONSJuly 2016October 2018Allow2811YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SALMON, KATHERINE D.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
3
Examiner Affirmed
2
(66.7%)
Examiner Reversed
1
(33.3%)
Reversal Percentile
49.5%
Lower than average

What This Means

With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
10
Allowed After Appeal Filing
5
(50.0%)
Not Allowed After Appeal Filing
5
(50.0%)
Filing Benefit Percentile
77.4%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 50.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner SALMON, KATHERINE D - Prosecution Strategy Guide

Executive Summary

Examiner SALMON, KATHERINE D works in Art Unit 1682 and has examined 108 patent applications in our dataset. With an allowance rate of 73.1%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner SALMON, KATHERINE D's allowance rate of 73.1% places them in the 37% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by SALMON, KATHERINE D receive 2.81 office actions before reaching final disposition. This places the examiner in the 82% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by SALMON, KATHERINE D is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +39.8% benefit to allowance rate for applications examined by SALMON, KATHERINE D. This interview benefit is in the 87% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 17.8% of applications are subsequently allowed. This success rate is in the 16% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 31.4% of cases where such amendments are filed. This entry rate is in the 46% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 72.7% of appeals filed. This is in the 61% percentile among all examiners. Of these withdrawals, 62.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 72.7% are granted (fully or in part). This grant rate is in the 79% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 17.6% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.